What treatment is approved for the prevention of osteoporosis in postmenopausal women?
Raloxifene
Bazedoxifene /conjugated oestrogens
MHT
Bazedoxifene
All of the above
Which of the following statements is correct?
Raloxifene reduces the risk of hip fractures
Bazedoxifene reduced risk of non-vertebral fractures
Tibolone decreases the risk of non-vertebral fractures
Raloxifene increases the risk of breast cancer
Bazedoxifene reduces the risk of venous thromboembolism
Combined oestrogen-progestogen formulations are recommended for women who have had a hysterectomy
MHT is effective in preventing bone loss in postmenopausal women
There is no limit to the duration of MHT
Only an oral formulation of oestrogen is available
Tibolone decreases the risk of stroke
What is the main characteristic of Selective Oestrogen Receptor Modulators (SERMs) such as raloxifene?
They act as oestrogen agonists in all tissues
They have no effect on bone mineral density (BMD)
They reduce the risk of new vertebral fracture
They decrease the risk of venous thromboembolism
They stimulate endometrial growth in postmenopausal women
Which of the following is a contraindication for the use of MHT?
Low bone mineral density
History of venous thromboembolism (VTE)
Light hot flashes
Women under 60 years of age
Women within 10 years of menopause
What is a major risk associated with tibolone therapy in postmenopausal women?
Increased risk of breast cancer
Decreased bone mineral density
Increased risk of stroke
Increased levels of bone turnover markers
Decreased risk of bleeding